[Department of Error] Department of Error

This article serves as a correction to a previously published study. The original study, titled "Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE)", was published in The Lancet. Specifically, it appeared in the 2025 volume, issue 406, pages 33 to 42. The correction addresses an update to the list of study investigators found in the appendix. This change was implemented on June 18, 2026. This information is important for readers to have accurate data regarding the authors. The ENERGIZE study was a phase 3, international, randomised, double-blind, placebo-controlled trial.